Cinacalcet Shortage: What Providers and Prescribers Need to Know in 2026

For nephrologists and other clinicians managing secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease (ESKD), cinacalcet (Sensipar) remains a cornerstone of oral calcimimetic therapy. While cinacalcet is not currently listed on the FDA's Drug Shortage Database as of 2026, prescribers continue to encounter patients who report difficulty accessing the medication at retail pharmacies. This article provides a clinical overview of the supply landscape and practical guidance for managing affected patients.

Current Supply Status of Cinacalcet (2026)

Generic cinacalcet entered the U.S. market following patent expiration of Sensipar around 2019. Multiple manufacturers — including Aurobindo Pharma and others — now produce cinacalcet in 30 mg, 60 mg, and 90 mg tablet strengths. This generic competition has substantially improved supply resiliency and reduced average costs to patients.

Despite no formal nationwide shortage, clinicians should be aware that:

Community and retail pharmacies may not stock cinacalcet routinely due to its specialty-tier status and narrow prescribing population.

Generic manufacturer-specific supply disruptions can affect availability at pharmacy chains that stock only one manufacturer's version.

Insurance prior authorization or step therapy requirements can create apparent access barriers that mimic drug unavailability.

Medicare ESRD bundled payment policy governs how in-center dialysis patients access calcimimetics, and transitions between care settings can temporarily disrupt access.

Clinical Risks of Cinacalcet Interruption

Abrupt discontinuation of cinacalcet may result in a rapid rebound elevation of parathyroid hormone (PTH), calcium, and phosphorus. This is particularly concerning for patients with higher baseline PTH levels or a history of severe SHPT. Key management principles include:

Counsel patients proactively to allow adequate lead time when refilling cinacalcet.

Monitor PTH, calcium, and phosphorus labs more frequently if an interruption occurs.

For patients approaching dangerously elevated PTH, consider bridging with vitamin D analogs if the cinacalcet delay is expected to be short.

Therapeutic Alternatives for Providers to Consider

When cinacalcet access is persistently challenging, clinicians should evaluate switching to an IV calcimimetic or a vitamin D analog. Key considerations:

Etelcalcetide (Parsabiv)

Etelcalcetide, FDA-approved in 2017, is an IV calcimimetic administered thrice weekly at the end of hemodialysis. Randomized trials demonstrated superior PTH reduction compared to cinacalcet. Key prescribing considerations include:

Discontinue cinacalcet at least 7 days before initiating etelcalcetide to prevent severe hypocalcemia.

Ensure corrected serum calcium is at or above lower limit of normal prior to initiation.

Etelcalcetide is not approved for peritoneal dialysis patients.

If switching back to cinacalcet, discontinue etelcalcetide for at least 4 weeks before restarting cinacalcet.

Paricalcitol and Calcitriol

For patients whose PTH elevation is driven partly by vitamin D deficiency, paricalcitol (IV or oral) or calcitriol can serve as bridge or adjunctive therapy. These agents carry risk of hypercalcemia and hyperphosphatemia and are most appropriate when calcium and phosphorus levels are within target. They do not substitute for calcimimetics in patients with calcium-phosphorus dysregulation.

Pharmacological Reminder: Key Cinacalcet Drug Interactions

Cinacalcet is a strong inhibitor of CYP2D6 and is partially metabolized by CYP3A4. Clinically relevant interactions to assess when managing patients on cinacalcet:

CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): May significantly increase cinacalcet plasma levels — monitor serum calcium and PTH closely; dose adjustment of cinacalcet may be warranted.

CYP2D6 substrates (tricyclic antidepressants, certain antipsychotics, some beta-blockers, opioids): Cinacalcet inhibits CYP2D6, potentially increasing levels of co-administered CYP2D6 substrates.

Etelcalcetide: Contraindicated concurrently — severe, potentially life-threatening hypocalcemia risk.

How medfinder Supports Your Patients

When your patients have difficulty locating cinacalcet, medfinder for providers is a service that calls pharmacies to find which ones can fill your patient's prescription. Patients provide their medication, dosage, and location; medfinder contacts pharmacies on their behalf and texts results. This reduces the time between prescription writing and medication access.

See our companion article: How to help your patients find cinacalcet in stock.